93 related articles for article (PubMed ID: 17632021)
1. Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32).
Bueno C; Lopes LF; Menendez P
Blood Cells Mol Dis; 2007; 39(3):366-8. PubMed ID: 17632021
[No Abstract] [Full Text] [Related]
2. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.
Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ
Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
4. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.
Slotta-Huspenina J; Koch I; Richter M; Bink K; Kremer M; Specht K; Krugmann J; Quintanilla-Martinez L; Fend F
Leuk Res; 2008 Jan; 32(1):79-88. PubMed ID: 17629555
[TBL] [Abstract][Full Text] [Related]
7. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
9. [Both myeloma cells and bone marrow stromal cells are involved in the overproduction of interleukin 6 in multiple myeloma].
Ding S; Hou J; Sun A
Zhonghua Xue Ye Xue Za Zhi; 1998 Jun; 19(6):306-8. PubMed ID: 11243111
[TBL] [Abstract][Full Text] [Related]
10. Identification of a stroma-mediated Wnt/beta-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche.
Kim JA; Kang YJ; Park G; Kim M; Park YO; Kim H; Leem SH; Chu IS; Lee JS; Jho EH; Oh IH
Stem Cells; 2009 Jun; 27(6):1318-29. PubMed ID: 19489023
[TBL] [Abstract][Full Text] [Related]
11. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
Matsubayashi S; Nakashima M; Kumagai K; Egashira M; Naruke Y; Kondo H; Hayashi T; Shindo H
Pathol Res Pract; 2009; 205(9):626-33. PubMed ID: 19324500
[TBL] [Abstract][Full Text] [Related]
13. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
14. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin.
Matsuo Y; Drexler HG; Harashima A; Okochi A; Hasegawa A; Kojima K; Orita K
Leuk Res; 2004 Aug; 28(8):869-77. PubMed ID: 15203285
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32).
Kobayashi H; Saito H; Kitano K; Kiyosawa K; Gaun S; Aoki K; Narita A; Watanabe M; Uchimaru K; Motokura T
Acta Haematol; 1995; 94(4):199-203. PubMed ID: 8610478
[TBL] [Abstract][Full Text] [Related]
16. Bone lesions in molecular subtypes of multiple myeloma.
Robbiani DF; Chesi M; Bergsagel PL
N Engl J Med; 2004 Jul; 351(2):197-8. PubMed ID: 15247367
[No Abstract] [Full Text] [Related]
17. Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.
Tarsitano M; Palmieri S; Ferrara F; Riccardi C; Cavaliere ML; Vicari L
Cancer Genet Cytogenet; 2009 Dec; 195(2):164-7. PubMed ID: 19963117
[TBL] [Abstract][Full Text] [Related]
18. [Constitutive NF-kappaB activation in myeloma cells: its underlying mechanism and functional significance].
Otsuyama K
Rinsho Ketsueki; 2009 Jun; 50(6):461-7. PubMed ID: 19571505
[No Abstract] [Full Text] [Related]
19. Targeting Wnt pathway in lymphoma and myeloma cells.
Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
[No Abstract] [Full Text] [Related]
20. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
